Dr. Gomella Discusses Immunotherapy in Bladder Cancer

Leonard Gomella, MD
Published: Monday, Apr 10, 2017



Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Urologists have been using immune-based agents in the urinary tract for 20 to 30 years, making the bladder a natural home for immunotherapy, says Gomella.

Newer studies are focusing on the mechanisms of immunotherapy—determining that it fights cancers. Additionally, Gomella says, newer agents are geared more toward the systemic treatment of patients with advanced bladder cancer rather than localized disease, but those agents are in the pipeline.
 
SELECTED
LANGUAGE


Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.

Urologists have been using immune-based agents in the urinary tract for 20 to 30 years, making the bladder a natural home for immunotherapy, says Gomella.

Newer studies are focusing on the mechanisms of immunotherapy—determining that it fights cancers. Additionally, Gomella says, newer agents are geared more toward the systemic treatment of patients with advanced bladder cancer rather than localized disease, but those agents are in the pipeline.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x